5-Amino-1MQ side effects, risks and timelines: what the evidence actually covers

“What are the side effects of 5-Amino-1MQ?” is a fair question with an unusual answer: nobody has measured them in people. The compound has been studied in fat cells and in mice, mostly by one research group, and that work is where every claim about it begins, including the reassuring ones. This page lays out what those animal studies actually recorded about safety, two newer findings that matter for anyone swallowing a tablet, how long the effects took to show up in mice, and what “before and after” can honestly mean for a compound with no human results. For the full overview of what 5-Amino-1MQ is, see The Treatment Report’s 5-Amino-1MQ explainer.

Evidence level for everything below: cell and mouse studies only. We searched the ClinicalTrials.gov registry on October 12, 2026 for “5-amino-1MQ”, “5-amino-1-methylquinolinium” and “NNMT inhibitor” and found zero registered studies for each term.

What does 5-Amino-1MQ do?

5-Amino-1MQ is a small molecule, not a peptide, that blocks an enzyme called nicotinamide N-methyltransferase (NNMT). In cultured fat cells, blocking NNMT raised levels of NAD+ and SAM, two molecules involved in energy use, and suppressed fat building. In obese mice, that translated into weight and fat loss without the animals eating less. It is often sold next to peptides such as MOTS-c in online weight-loss categories and called a peptide, even though it is not one. Our guide to peptides for weight loss places it alongside the other compounds people use.

What are the side effects of 5-Amino-1MQ?

The honest answer is that 5-Amino-1MQ side effects in humans are unknown, because no human study has been published or registered. What exists is a short list of animal and lab observations, and they point in a reassuring direction within narrow limits:

• Short-term mouse studies saw no observable problems. In the 2018 founding study, a small dose-finding test in two obese mice found a daily level that was well tolerated with no observable adverse effects, and the 11-day main study reported none either.
• A 7-week study checked blood chemistry. In a 2021 study pairing the compound with a lower-calorie diet in obese mice, the authors wrote that repeated dosing over the 7-week period did not produce any adverse effects and was well tolerated, and serum chemistry markers were not significantly different between groups apart from two protein measures.
• A 2024 study saw blood counts change. In a 30-day study in obese mice, the higher-dose group had a lower total white blood cell count, driven by a 31% decrease in lymphocytes and a 50% decrease in monocytes compared with controls. The authors read this as less obesity-related inflammation, alongside improved liver enzymes. What a change like that would mean in a person has not been studied.
• Fat-precursor cells in a dish showed toxicity only at high concentrations. The 2018 paper found modest cytotoxicity at 100 to 300 µM and about 40% at 600 µM, far above the 10 µM concentration the authors used to block the enzyme in fat cells.

“No observable adverse effects” in mice means the researchers did not see obvious harm over weeks. It does not tell you about headaches, sleep, mood, digestion or anything else a person would notice and a mouse cannot report. We also checked FDA adverse-event data: a search of openFDA’s adverse event reports (data last updated July 30, 2026) for “5-amino-1MQ”, “5 amino 1MQ” and “5-amino-1-methylquinolinium” returned no matching reports on October 12, 2026. An empty search is not evidence of safety, and openFDA itself warns users to assume its results are unvalidated.

What are the risks associated with using 5-Amino-1MQ?

Beyond “unknown,” two findings from a 2024 study by the compound’s developers are the most concrete risk signals so far. Both come from Babula et al., 2024, in Diabetes, Obesity and Metabolism.

It also blocks MAO-A in a lab screen. When 5-Amino-1MQ was tested against a broad panel of receptors and enzymes, it showed no significant activity against any target except a 67.4% inhibition of monoamine oxidase-A (MAO-A). The authors list reducing that off-target activity as part of ongoing work to optimize the compound. MAO is the enzyme that prescription MAO inhibitor antidepressants block, and the label for one of them, phenelzine (Nardil), warns about hypertensive crises from high-tyramine foods and dangerous combinations with certain cough medicines and other drugs. Nobody has measured whether a 5-Amino-1MQ tablet inhibits MAO-A in a person, or by how much. It is a reason to be cautious about combining it with antidepressants or other drugs that act on the same system, and to raise it with a clinician or pharmacist.

It is poorly absorbed by mouth, at least in mice. In the same paper, a single oral dose in mice produced low blood levels that peaked after about 4 hours, giving an oral bioavailability of 3.5%, which the authors attributed to limited absorption from the gut and heavy breakdown by the liver on first pass. Every mouse efficacy study described on this page gave the compound by injection. Since 5-Amino-1MQ is sold as an oral tablet, that form is the one with the least supporting data. No human absorption study exists, so whether people absorb more or less than mice is unknown.

Other risks follow from what has not been studied:

• Long-term use. The longest study we found ran eight weeks in mice. Months of daily use have never been studied.
• Interactions. NNMT sits on the pathway that handles vitamin B3 and methyl groups, and no study has tested 5-Amino-1MQ alongside niacin-type supplements, NAD+ precursors or common medications. Our longevity publication covers the NAD+ side of this in NAD+ versus peptides for longevity.
• Product quality. There is no approved version, so what is in a given tablet or vial depends on who made it. A Fortune reporter documented buying 10 vials of 5-amino-1MQ, which arrived as a bright-orange substance, from an online seller paid in crypto (June 4, 2026).
• Who funded the research. The later papers disclose that the senior author founded Ridgeline Therapeutics, a company developing NNMT inhibitors, and that co-authors are its employees. Independent replication is mostly missing.

People who are pregnant, managing a chronic condition, or taking prescription medication have no data to go on at all.

How long does 5-Amino-1MQ take to work?

In people, nobody knows, because it has never been tested in people. In mice, measurable changes showed up within days to weeks, depending on the study:

Mouse timelines do not convert into human weeks, and no study has tried to translate them. The 2024 obesity study also found that dose mattered: the lower-dose group gained about as much weight as the controls (5.2 g versus 5.4 g), while the higher-dose group gained 0.9 g. Combined with the poor oral absorption above, that makes any “it kicks in after X weeks” claim about tablets a guess.

What do 5-Amino-1MQ “before and after” results actually show?

The only measured before-and-after data for 5-Amino-1MQ comes from mice, and no human before-and-after result has been published. We do not show photos here, because a photo of a person cannot separate the compound from diet, training, other drugs or lighting. This is what was measured:

User reports, labeled as such: we do not yet have Community Insights data for 5-Amino-1MQ, so this page does not quote or summarize user posts about results or side effects. Any before-and-after you see online is a single person’s account, usually alongside diet changes, training or other compounds, about a product whose contents and absorption are unverified.

How does the safety evidence compare with other weight-loss compounds?

5-Amino-1MQ sits at the thin end of the evidence scale. PeptideAgent’s AOD-9604 vs 5-Amino-1MQ comparison reaches a similar verdict, noting that 5-Amino-1MQ has never been tested in people and has no human safety data of any kind. The comparison below is about how much is known about side effects, not about which works better:

The pattern is the opposite of what people sometimes assume: the compounds with long side-effect lists are the ones that were studied in thousands of people, and a short or empty list here means “not measured.” For what the studied drugs actually cause, see our guides to GLP-1 side effects and retatrutide side effects.

Is 5-Amino-1MQ safe to stack with other compounds?

No study has tested 5-Amino-1MQ in combination with MOTS-c, NAD+ precursors or GLP-1 drugs, so the safety of any stack is unknown. The closest evidence is the 2021 mouse study, where adding it to a lower-calorie diet accelerated weight and fat loss without reported adverse effects, and a diet is not a drug. Stacking also makes side effects harder to trace, because there is no way to tell which product caused what.

What to weigh before spending money on it

The cost question for 5-Amino-1MQ is less about price than about what the money buys: a compound with no human trials, sold as a tablet, the form that was absorbed worst in mice, with an off-target finding its own developers are working to remove. The Treatment Report’s overview covers listed prices and what drives them. If the goal is weight loss, the options with human evidence are worth reviewing with a licensed clinician first.

What is the community saying about 5-Amino-1MQ?

Our Community Insights tracker has not built a dataset for 5-Amino-1MQ yet, so we are not characterizing what users report. The published reporting we found is about how it is bought rather than how it feels: Fortune’s June 2026 investigation into crypto-paid peptide sellers used a 5-Amino-1MQ purchase as its test case, and the reporter quoted one enthusiast saying it “makes a lot more sense for high-level competitive athletes” than for a first-time buyer. When tracker data exists, it will be summarized here with dates and sources.

Status: Not FDA-approved; sold by some telehealth providers as a compounded prescription. What this status means.

Educational information only, not medical advice. Study figures are as reported in the cited papers as of October 12, 2026, and come from cells and mice, not people.